STAREE-HEART: A randomized placebo-controlled trial of atorvastatin effects on a marker of cardiac aging in older individuals without prior cardiovascular disease events: Protocol and baseline description of participants
Authors' conclusion
The STAREE-HEART ancillary study will provide mechanistic detail concerning myocardial dysfunction and its consequences, to determine if atorvastatin affects left ventricular systolic function associated with aging.
Study context
- Population
- Healthy adults ≥70 years without prior CVD events
- Participants
- 369 adults
- Comparison
- Atorvastatin vs placebo
- Primary endpoint
- Change in global longitudinal strain (GLS), a measure of left ventricular (LV) systolic function
- Follow-up
- 3 years
Methodological detailsdouble-blind, placebo-controlled, ancillary study nested in the STAtins in Reducing Events in the Elderly (STAREE) primary prevention trial, Planned 184 participants per group to detect a 2.0 percentage-point global longitudinal strain (GLS) difference at 3 years (SD = 5, 15% attrition, power >90%)
- Double-blind
- Placebo-controlled
- Ancillary study nested in the STAREE primary prevention trial
- Planned 184 participants per group to detect a 2.0 percentage-point GLS difference at 3 years (SD = 5, 15% attrition, power >90%)
Primary result
As reported in the abstract
Baseline characteristics (all participants)
Atrial fibrillation (AF) detected on screening
4.5%
Further findings
Baseline mean GLS by sex (females vs males)
- Similar between females and males: 19.4% vs 19.0%
Baseline mean GLS by age (70–74 vs ≥75 years)
- Slightly higher in those aged 70 to 74 vs ≥75 years: 19.4% vs 18.6%
Original publication
STAREE-HEART: A randomized placebo-controlled trial of atorvastatin effects on a marker of cardiac aging in older individuals without prior cardiovascular disease events: Protocol and baseline description of participants. Am Heart J. Published 12 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →